Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of $0.32, $0.91 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $773.69 million versus the consensus estimate of $643.2 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.